Skip Navigation



Hum. Reprod. Advance Access published online on December 17, 2004

Human Reproduction, doi:10.1093/humrep/deh574
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
20/2/549    most recent
deh574v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Heinemann, K.
Right arrow Articles by Heinemann, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heinemann, K.
Right arrow Articles by Heinemann, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction © European Society of Human Reproduction and Embryology 2004; all rights reserved
Received March 18, 2004
Revised June 21, 2004
Accepted September 29, 2004

Article

Attitudes toward male fertility control: results of a multinational survey on four continents

Klaas Heinemann 1*, Farid Saad 2, Martin Wiesemes 2, Steven White 2, and Lothar Heinemann 1

1 Center for Epidemiology & Health Research Berlin, Berlin, Germany
2 GBU Gynaecology and Andrology, Schering AG, Berlin, Germany

* To whom correspondence should be addressed.
Klaas Heinemann, E-mail: klaas{at}zeg-berlin.de


   Abstract

BACKGROUND: Following extensive research activity to develop an effective agent to control male fertility, such a product may be available for use within ~5 years. However, little is known concerning contraceptive knowledge, desires and attitudes of men in different countries, and their acceptance of male fertility control (MFC). METHODS: A survey of >9000 males aged 18-50 years was performed in nine countries on four continents in 2002. The objective was to compare, on a cross-cultural basis, the knowledge, attitudes and acceptability of MFC among men and assess their willingness to use such a method. RESULTS: Between 50 and 83% of the male respondents currently use contraceptive methods, and 55-81.5% reported that both partners participate in selecting the method of contraception employed. Overall acceptance of hormonal MFC was high (>55%), with 28.5-71.4% of survey participants of various nationalities expressing the willingness to use such a method. CONCLUSION: While MFC appears to be well accepted overall, the willingness to use this type of contraception varies widely between differing population groups. The specific characteristics and profile of any MFC product will have to be carefully evaluated to accurately assess its acceptance, both by men and their female partners.

Keywords: administration route; contraception; male fertility control; multinational; survey.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
E. Nieschlag
Male Hormonal Contraception: Love's Labour's Lost?
J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1890 - 1892.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Y. Liu and R. I. McLachlan
Male Hormonal Contraception: So Near and Yet So Far
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2474 - 2476.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Mommers, W. M. Kersemaekers, J. Elliesen, M. Kepers, D. Apter, H. M. Behre, J. Beynon, P. M. Bouloux, A. Costantino, H.-P. Gerbershagen, et al.
Male Hormonal Contraception: A Double-Blind, Placebo-Controlled Study
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2572 - 2580.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
S. T. Page, J. K. Amory, and W. J. Bremner
Advances in Male Contraception
Endocr. Rev., June 1, 2008; 29(4): 465 - 493.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
J. K. Amory, T. F. Kalhorn, and S. T. Page
Pharmacokinetics and Pharmacodynamics of Oral Testosterone Enanthate Plus Dutasteride for 4 Weeks in Normal Men: Implications for Male Hormonal Contraception
J Androl, May 1, 2008; 29(3): 260 - 271.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M.C. Meriggiola, S. Cerpolini, W.J. Bremner, M.T. Mbizvo, K.M. Vogelsong, G. Martorana, and G. Pelusi
Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men
Hum. Reprod., August 1, 2006; 21(8): 2033 - 2040.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
K. L. Matthiesson and R. I. McLachlan
Male hormonal contraception: concept proven, product in sight?
Hum. Reprod. Update, July 1, 2006; 12(4): 463 - 482.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A. V. Marcell, K. Plowden, and S. M. Bowman
Exploring older adolescents' and young adults' attitudes regarding male hormonal contraception: applications for clinical practice
Hum. Reprod., November 1, 2005; 20(11): 3078 - 3084.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.